Evidence map›Paper›PMID 42540350›Full record

ArticleClinical case reports2026

Evidence-Based Nursing Management During Mavacamten Therapy in an 89-Year-Old Patient With Symptomatic Hypertrophic Obstructive Cardiomyopathy: A Case Report.

Feifei Wang

Abstract read
In one paragraph

Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Feifei WangDepartment of Cardiovascular Medicine Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University Guangzhou China.ORCID https://orcid.org/0009-0000-5936-8094

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In older patients receiving mavacamten, a reduction in NT-proBNP levels may coexist with persistent severe LVOTO. Nurses should interpret this biomarker-echocardiography discordance as a safety signal and maintain structured cardiovascular surveillance rather than assuming treatment success based solely on biomarker improvement.

Indexed as

80 and over agedcase reportshypertrophic cardiomyopathyMavacamtennursing care

Identifiers

PMID42540350
PMCPMC13425588

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.